Human Leukocyte Interferon in the Treatment and Prophylaxis of Acute Hemorrhagic Conjunctivitis
Legend. Results of human leukocyte interferon (HLI) in the treatment and prophylaxis of acute hemorrhagic conjunctivitis (AHC) due to enterovirus 70 (EV 70) in patients in the Dominican Republic. t By X 2 with Yates's correction (uncorrected X 2 = .01).
Summary
Participants were selected from among patients who were examined for presumed AHC during the outbreak period, were identified within 24 hr of onset of symptoms, and who met the case definition [1] . Patients were randomized in a double-blind setting to one of the two following groups: (1) Corp, Tuckahoe, NY) ophthalmic drops packaged in a sterile solution administered at a dosage of one drop, two times a day (50,000 units per drop) for five days and (2) a placebo group receiving a commercial artificial tear solution. Both eyes were treated in every case, even if only one eye was affected. Unaffected family members accompanying any of the study patients were also invited to participate in the study. Within each household, all members who participated, both affected and unaffected, received the same treatment (HLI or placebo).
Eye swabs obtained early in the outbreak were processed and inoculated into tube cultures of human embryonic lung fibroblast (HELF) cells maintained on Eagle's minimal essential medium with 1070 fetal calf serum and incubated on a roller drum at 33 C. Viruses isolated were identified by serum-neutralization tests in HELF cells with antiserum against prototype EV70 (strain J 670/71). Sera were tested for neutralizing antibodies by a micromethod using human rhabdomyosarcoma cells [2] .
Two of the 15 cultures taken from nonparticipant patients were found to be positive for EV70. The viral isolation rate was low but similar to that noted by investigators in other outbreaks [3] , and no other possible pathogens were identified. All 15 serum specimens taken from participants at entry into the study were negative (peak titer, <1 :4) for EV70 neutralizing antibody. Of nine patients from whom serum was collected on day seven of the AHC infection, three had seroconverted. The only two patients who volunteered specimens on day 28 had seroconverted from <1:4 to 1:64 and 1:128 against EV70. Serological and viral-culture results support the assumption that the AHC outbreak was caused by EV70 infection.
Placebo-and interferon-treatment groups were comparable at entry to the study with respect to demographic data, severity of symptoms, and clinical-examination findings. Frequencies of symptoms and signs were typical of those reported in other descriptions of AHC epidemics [1] . Although the number of patients observed was small, the clinical course of AHC was not different in the HLI and saline placebo-treated groups. No adverse responses, as indicated by emergence or persistence of symptoms found on clinical examination, could be attributed to effects of HLI treatment.
Of greater interest, perhaps, are the results of the prophylactic use of HLI. We examined the impact of interferon treatment on both progression of AHC to contralateral eyes (for those few cases in which AHC was unilateral at presentation) and intrahousehold spread of infection. The single interferon-treated patient whose disease progressed to bilateral infection was also the sole participant who discontinued treatment prior to completion of the five-day course of therapy. Because of the small numbers involved, however, even eliminating this case does not make the results statistically significant (P = .06 by Fisher's exact test). Despite the small number of unaffected household members enrolled, a significant effect was observed on intrahousehold spread of infection to unaffected nonparticipant household members. That no secondary-spread cases occurred among unaffected household members who received either placebo or HLI suggests that use of ophthalmic drops was not a source of infection and may possibly be ascribed to the education in hygienic practice provided to both HLI and saline control-treated families.
